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Subjective and Objective Measures of Symptoms, Function, 
and Outcome in Patients With Degenerative Spine Disease
Nicolai Maldaner1 and Martin Nikolaus Stienen2
INTRODUCTION
The management of patients with degenerative diseases 
of the spine requires reliable measures of symptoms, func-
tion, and outcome. Choice of conservative or surgical ther-
apy in this cohort is complex and depends on many factors, 
including the history, quality, and severity of pain; functional 
limitations; and health- related quality of life (HRQOL) (1,2). 
An accurate and thorough evaluation of both the subjective 
and objective condition is helpful to select adequate treat-
ment for the individual patient (3). In recent years, subjective 
patient- reported outcome measures (PROMs) in the form 
of questionnaires have been established as the gold stand-
ard for the clinical evaluation of spine patients (4). General 
pain measures, including the visual analog scale (VAS) or the 
numeric rating scale (NRS) for low back pain (LBP) or irradi-
ating extremity (arm/leg) pain, are among the most commonly 
used PROMs. However, they are generic and not specific 
tools for spinal diseases (5). The Oswestry Disability Index 
(ODI), which is included in this review, is a prime example of 
an in- depth validated PROM and represents one of the most 
established instruments for a variety of different diseases of 
the lumbar spine (6,7). There is a broad variety of degener-
ative spine diseases, some of which are unspecific, whereas 
others (eg, lumbar spinal stenosis [LSS]) present with charac-
teristic symptoms (eg, neurogenic claudication) that can be 
addressed by disease- specific tools (8). Cervical or thoracic 
degenerative spine disease may present with both radicular 
pain and/or myelopathy; outcome measures have to account 
for these different clinical manifestations (9).
Apart from subjective PROMs, objective measures of 
function are gaining increasing attention in spine research 
and have found their way into clinical practice (8,10). 
Measurements like the Timed Up- and- Go (TUG) test and 
the motorized treadmill test (MTT) assess a patient’s objec-
tive functional impairment (OFI) and add a new dimension to 
the comprehensive patient evaluation (11). Because patients 
prefer objective functional tests rather than questionnaires 
and considering the continuous validation and standard-
ization of objective outcome measures, we included the 
two most frequently applied tests of this relatively new field 
of outcome assessment in this review (8,12).
Degenerative disease of the spine encompasses a wide 
range of different pathologies and disease- specific symptoms. 
This leads to an even greater number of outcome measures 
that cannot all be included in the scope of this review. How-
ever, this article should provide the reader with a comprehen-
sive summary of carefully selected instruments (Tables 1 and 
2) (5,8,13).
PATIENT- REPORTED OUTCOME MEASURES
SPINAL STENOSIS MEASURE (SSM)
Description
Purpose. The SSM was developed in 1995 by Stucki 
et al as a short self- administered questionnaire to assess pain- 
related disability and health- related parameters in patients 
diagnosed with LSS (14). The SSM is also known as the 
Zurich Claudication Questionnaire, the Swiss Spinal Stenosis 
Questionnaire, or the Brigham Spinal Stenosis Questionnaire. 
The measure specifically addresses symptoms and functional 
deficits resulting from neurogenic claudication (14). It also 
includes an optional domain on patient satisfaction regarding 
the result of surgery. The SSM is one of the leading PROMs 
used by both spine surgeons and rheumatologists (5,15).
1Nicolai Maldaner, MD: University Hospital Zurich and University of 
Zurich, Zurich, Switzerland, and Cantonal Hospital St. Gallen, St. Gallen, 
Switzerland; 2Martin Nikolaus Stienen, MD, FEBNS: University Hospital 
Zurich and University of Zurich, Zurich, Switzerland, and Stanford University 
Hospital and Clinics, Stanford, California.
No potential conflicts of interest relevant to this article were reported. 
Address correspondence to Martin Nikolaus Stienen, 
MD, FEBNS, University Hospital Zurich, Department of Neurosurgery, 
Frauenklinikstrasse 10, Zurich 8091, Switzerland. E-mail: mnstienen@ 
gmail.com.
Submitted for publication January 5, 2020; accepted in revised form April 
2, 2020.
MALDANER AND STIENEN 184       |
Content. The SSM contains three scales, with seven ques-
tions on symptom severity (SSM symptoms), five questions on 
physical function (SSM function), and six questions on satisfac-
tion (SSM satisfaction). The SSM symptom scale encompasses 
a pain subdomain (three items) and a neuroischemic subdomain 
(four items).
Number of items. Eighteen items.
Response options/scale. Each item is measured on a 
three- to five- point ordinal scale, ranging from the best scenario to 
the worst scenario.
Recall period for items. The scale relates to symptoms 
experienced over the past month.
Cost to use. None.
How to obtain. The items are reported in the original publi-
cation (14). A copy is provided as an appendix to this article (Eng-
lish version).
Practical application
Method of administration. The SSM is self- administered 
by patients using paper and pen. Administration by telephone is 
also possible.
Scoring. The symptom severity score is the 
unweighted mean of the first seven questions; the resulting score 
indicates greater symptom severity. The first six items are scored 
from 1 to 5, whereas the seventh item has only three possible 
responses corresponding to scores of 1, 3, or 5. The symptom 
severity score can be further divided into a subscale for pain 
(questions one through three) and neuroischemic symptoms 
(questions four through seven). The physical function score is 
calculated as the unweighted mean of the following five ques-
tions, all scored from 1 to 4, with higher scores representing 
greater disability. The third scale relates to patient satisfaction 
after treatment, with higher scores indicating greater satisfac-
tion. The unweighted mean is only valid if no more than one item 
is missing in the SSM function and SSM satisfaction scores and 
no more than two items are missing in the SSM symptom score. 
Some authors prefer to depict the SSM as the sum score with-
out taking the unweighted mean.
Score interpretation. An unweighted mean is calculated 
for all three subscales. The SSM symptom severity score ranges 
from 1 (no symptoms) to 5 (maximal symptoms), which is further 
divided into the pain subscales (scores between 1 and 5) and 
neuroischemic symptom subscale (scores between 1 and 5). The 
SSM functions score ranges from 1 (no disability) to 4 (maximum 
disability), and the SSM satisfaction score ranges from 1 (very sat-
isfied) to 4 (very dissatisfied). When the SSM is declared as a sum 
score, the SSM symptom score ranges from 7 (no symptoms) to 
35 (maximal symptoms), the SSM functions score ranges from 
5 (no disability) to 20 (maximum disability), and SSM satisfaction 
score ranges from 6 (very satisfied) to 24 (very dissatisfied).
Respondent time to complete. The SSM is relatively 
short and simple to fill out. It can be completed by the patient in 
less than 5 minutes.
Administrative burden. The SSM requires little adminis-
trative burden. The time to score (by hand) is short. No training is 
required.
Translations/adaptations. Translations are available in 
German and English. There are published adaptations in Spanish, 
Chinese, French, Polish, Norwegian, Iranian, Korean, Slovenian, 
and other languages, which showed satisfactory to excellent reli-
ability and validity (15–23).
Psychometric information
Floor and ceiling effects. The authors are not aware of 
any studies reporting on floor or ceiling effects of the scales.
Reliability. The reliability in test- retest assessment consist-
ently scores of more than 80% to 90% agreement (24–26).
Validity. The SSM has been validated against the self- 
paced walking test, the ODI, the Oxford Spinal Stenosis Score, 
the Short Form 36 (SF- 36), the Health Utilities Index, the Center 
for Epidemiologic Studies Depression Scale, and other measures 
with high correlations (25–27). Several studies have supported the 
construct validity of the SSM and psychometric properties and 
physical function in the LSS population (25,27,28).
Responsiveness. Standardized response means (SRMs) 
are reported to be 1.07 for the SSM function scale and 0.96 for 
the SSM symptom scale in the original study with 130 patients 
(28). In a subsequent independent study among 91 patients 
with LBP, the SRM of SSM function (1.00) and SSM symptom 
(1.43) were confirmed, and the composite SSM average score 
even increased in responsiveness (1.50) (29). Because of its dis-
ease specificity, the SSM has been shown to be more responsive 
than the Sickness Impact Profile and the Roland- Morris Disability 
Questionnaire (RMDQ) in assessing patients with LSS (28).
Minimal clinically important differences. Stucki et al 
reported a difference in the physical function scale and symptom 
severity scores between the unsatisfied and somewhat satisfied 
patients of 0.52 (13%) and 0.48 (9.6%) (14).
MEASURES OF SYMPTOMS, FUNCTION, AND OUTCOME IN SPINE CARE |      185
Generalizability. The SSM is specific to symptoms and 
functional deficits characteristic of neurogenic claudication. For 
LSS, excellent generalizability has been proven by consistent 
results across multicultural studies (16–23).
Use in clinical trials. The SSM has been used in various 
recent studies and clinical trials (30–33).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The SSM is a short disease- specific ques-
tionnaire for patients with LSS with three different subscales, 
namely, symptom severity, physical function, and satisfac-
tion. The SSM proved to be the most precise in patients with 
LSS when compared with the ODI or the Oxford Claudication 
Score (25).
Caveats and cautions. A publication by Comer et al used 
Rasch analysis to evaluate the psychometric properties of the 
SSM (24). In their study, the SSM symptom scale, by measuring 
pain and neuroischemic symptoms as two separate constructs, 
failed to function as a unidimensional domain. Because of this, 
the SSM symptom scale was further subdivided into the two 
separate subscales. The SSM function proved valid for group 
comparison, although question 11 was not considered clini-
cally meaningful (24).
Clinical usability. The SSM has established psychomet-
ric properties, and both administrative and respondent burdens 
are low. It is frequently used to assess and monitor outcome. As 
the current gold standard of outcome assessment in patients 
with LSS, it has been endorsed by the North American Spine 
Society and termed “best and most specific outcome measure 
for LSS” (34).
Research usability. The SSM is widely used in clinical 
research. The SSM symptom scale should be further subdivided 
into the SSM pain symptom and SSM neuroischemic symptom 
scales to adequately address these separate conditions.
CORE OUTCOME MEASURES INDEX BACK 
(COMI BACK)
Description
Purpose. Ever since a multinational group of experts pro-
posed the COMI as a standardized outcome assessment in LBP 
research in 1998, this short multidimensional outcome meas-
ure has been thoroughly validated. It is widely used, especially 
to monitor outcomes in patients with various spinal disorders who 
are undergoing surgery or any form of intervention (35–37). Initially 
proposed as a set of six questions, a seventh item (overall quality 
of life) was added in 2005 by Mannion et al to construct what is 
known as the COMI Back (38). A validated and reliable version 
designed for cervical spine diseases, the Core Outcome Meas-
ures Index Neck, is also available (39,40).
Content. The COMI Back focuses on the patient’s per-
spective (29). Following this premise, it covers the domains of 
pain intensity (LBP and leg/buttock pain), back- related function, 
symptom- specific well- being, general quality of life, and social/
work disability. A further part covers patient satisfaction after sur-
gical treatment.
Number of items. Seven items. (There are an additional 
four questions at follow- up that cover patient satisfaction and 
treatment results.)
Response options/scale. The first two questions regard-
ing pain intensity are measured on a 0 to 10 NRS. The other 
five items are measured on a five- point Likert scale ranging from 
“best” to “worst.”
Recall period for items. All items refer to the last week 
(except for disability, which refers to the last 4 weeks).
Cost to use. None.
How to obtain. A copy in different languages (including 
English, German, French, and Spanish) can be downloaded from 
the EUROSPINE Spine Tango registry website (https://www.euros 
pine.org/forms.htm).
Practical application
Method of administration. The COMI Back is self- 
administered by patients using paper and pen or online forms.
Scoring. The higher of the two pain scores (scores of 0- 10) 
is taken as the pain intensity score. The other six items on the five- 
point Likert scales correspond with scores of 0, 2.5, 5.0, 7.5, and 
10, respectively. The average of the two disability items form the 
disability score. The five domain scores for pain intensity, back- 
related function, symptom- specific well- being, general quality of 
life, and disability are then averaged to give a COMI Back score 
that ranges from 0 to 10.
Score interpretation. Scores range from 0 (best) to 10 
(worst).
Respondent time to complete. The COMI Back is rel-
atively short and simple to fill out. It can be completed by the 
patient in less than 5 minutes.
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Administrative burden. The COMI Back requires little 
administration burden. The time to score (by hand) is short. No 
training is necessary.
Translations/adaptations. The COMI Back is available 
and cross- culturally validated in many languages, including Eng-
lish (38), German (38), Korean (41), Italian (42), French (43), Turkish 
(44), and Japanese (45) among others.
Psychometric information
Floor and ceiling effects. In one of the original articles, 
floor or ceiling effects in the range of 20% to 50% were observed 
for some items of the COMI Back before surgery (function and 
symptom- specific well- being) and after surgery (disability and 
function) (40).
Reliability. Several research groups examined the psy-
chometric properties of the COMI Back in patients with various 
pathologies presenting with LBP. The test- retest reliability con-
sistently scored highly, with an intraclass correlation coefficient 
(ICC) of 0.8 to 0.9 or more. High internal consistency for the core 
item index was shown for patients with chronic LBP (Cronbach’s 
α = 0.90 or more); however, less was shown in patients with acute 
osteoporotic fractures (Cronbach’s α = 0.64 or more) (38,40,46).
Validity. Good construct validity of the score was demon-
strated by a moderate to high correlation with reference question-
naires, including the RMDQ, the SF- 36, and the ODI (r = 0.60- 0.79) 
(38,46). The item symptom- specific well- being, however, showed 
little correlation to other measures (r = 0.25- 0.31), which might 
indicate that this item delivers unique information that may be of 
importance to the multidimensional nature of the overall index (38).
Responsiveness. Internal responsiveness corresponding 
with the SRM at the 12- month follow- up in a cohort of 91 patients 
undergoing surgery for LSS showed great responsiveness (SRM 
1.44), which was similar to or better than the SSM average (1.50), 
the RMDQ (1.13), and the NRS pain (1.28) (29). In the same 
cohort, external responsiveness—meaning the strength of corre-
lation between its change in scoring and the change in other out-
come instruments—showed moderate correlation with the SSM 
(r = 0.62) and RMDQ (r = 0.43). In an area under the receiver oper-
ating characteristics (AUROC) curve analysis, good discriminative 
ability between good and bad outcomes was demonstrated (area 
under the curve of more than 0.83) (30).
Minimal clinically important differences. One of 
the original studies examining the COMI Back in 277 patients 
with LBP reported a minimum clinically important difference 
for improvement (MCIDimp) as a two- to three- point decrease, 
depending on the anchor used to indicate treatment success 
(38). In a group of 3056 patients undergoing spine surgery for 
a variety of indications, the groups’ mean MCIDimp at 12 months 
was −2.6 points, and the minimum clinically important difference 
for deterioration (MCIDdet) was 1.2 points. AUROC curves of 
0.88 for the MCIDimp and 0.89 for the MCIDdet indicated good 
discriminative ability. The cutoffs for individual improvement and 
deterioration were −2.2 points or less (sensitivity 81%, specificity 
83%) and 0.3 points or more (sensitivity 83%, specificity 88%), 
respectively (36).
Generalizability. Psychometric properties and sensitivity 
to change of the COMI Back are strong in patients with LBP from 
a variety of causes (38,40,46,47). Thus, it can be applied to a 
broad range of patients with LBP.
Use in clinical trials. The COMI Back has been used 
in multiple clinical trials (48–50).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The COMI Back is a short but independently and 
repeatedly validated outcome measure for a variety of different 
pathologies presenting with LBP and leg pain. It is easily acces-
sible and is associated with a low burden for both patients and 
physicians.
Caveats and cautions. As in other back- specific out-
come measures (51,52), the COMI Back’s values for the MCIDdet 
are lower than those for the MCIDimp, indicating that the COMI is 
less responsive to deterioration than to improvement (36).
Clinical usability. The COMI Back has shown great psy-
chometric properties and is brief enough to be practical for routine 
clinical use and quality management. Based on these values, it 
has been incorporated into the European EUROSPINE registry as 
an outcome questionnaire of choice (53).
Research usability. The availability and ease of administra-
tion is meant to encourage clinicians and researchers to collaborate 
in registries and research projects on a national and international 
level (54). However, on an international level, outcomes measures 
like the ODI and RMDQ are still more established (5).
NECK DISABILITY INDEX (NDI)
Description
Purpose. Outcome research in cervical spine patients is 
historically less developed compared with lumbar spine patients 
(5,55). The NDI is one of the best established and most commonly 
used PROMs for chronic neck pain (56,57). Originally published in 
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1991, it is also known as the Vernon- Mior Disability Index or the 
Neck Pain Disability Index (58,59).
Content. The NDI measures pain and disability in patients 
with neck pain. The NDI covers the domains of pain intensity, per-
sonal care, lifting, work, headache, concentration, sleeping, driv-
ing, reading, and recreation.
Number of items. Ten items.
Response options/scale. Each of the 10 items are scored 
on a six- point Likert scale ranging from 0 (no pain/disability) to 5 
points (maximal pain/disability).
Recall period for items. The questions refer to the current 
clinical condition and pain intensity. The exact time frame is not 
defined.
Cost to use. None.
How to obtain. Copies in English and other languages can 
be found in published sources or from the EUROSPINE Spine 
Tango registry website (https://www.euros pine.org/forms.htm) 
(56,58,59).
Practical application
Method of administration. The NDI is self- administered 
by patients using paper and pen.
Scoring. All 10 items are scored from 0 to 5. Numeric 
responses are summed up to a total score ranging from 0 (best) 
to 50 (worst). The developer and others recommend scoring the 
NDI out of 50 points. If three or more items are missing, the ques-
tionnaire is not valid. If two or fewer items are missing, the score 
should be normalized to 50 (58,59). Besides presenting raw test 
results, many groups have expressed the score as a percentage, 
ranging from 0% to 100% neck disability.
Score interpretation. No consensus exists regarding 
score interpretation. The original developers suggested the fol-
lowing: scores between 0 and 4 represent no disability, scores 
between 5 and 14 represent mild disability, scores between 15 
and 24 represent moderate disability, scores between 25 and 34 
represent severe disability, and scores greater than 35 represent 
complete disability (56).
Respondent time to complete. The NDI is relatively short 
and simple to fill out. It can be completed by the patient in 3 to 
8 minutes (56).
Administrative burden. The NDI requires no administra-
tion burden and takes less than 3 minutes to score by hand. No 
training necessary.
Translations/adaptations. The NDI was originally devel-
oped in English but has been culturally adapted and translated 
into several languages including German (60,61), Spanish (62), 
Arabic (63), Chinese (64), Turkish (65), Japanese (66), Polish (67), 
Finnish (68), Greek (69), Portuguese, and other languages (70).
Psychometric information
Floor and ceiling effects. Patients with baseline score in 
the lower 10th and the upper 90th percentile are subject to sig-
nificant floor or ceiling effects, respectively. This is why caution is 
required when using the NDI to monitor outcome in these high- or 
low- performing patients (56,71,72).
Reliability. A systematic review published in 2009 analyzed 
41 studies that examined at least one aspect of the psychomet-
ric properties of the NDI. A high test- retest reliability was demon-
strated in populations with both acute and chronic neck pain, with 
a reliability coefficient of more than 0.90 in most studies (56).
Validity. The NDI score correlates strongly (r of more than 
0.70) with other neck disability measures, including the Neck Pain 
and Disability Scale, the Cervical Spine Outcome Questionnaire, 
the Disability Rating Index, and the VAS pain scale. Furthermore, 
high Cronbach’s α scores of 0.70 to 0.96 show good internal con-
sistency (56,57,60,70). The NDI is, however, only moderately cor-
related with both physical and mental aspects of general health as 
assessed by the SF- 36 (56).
Responsiveness. The NDI has a good ability to detect 
changes over time. The SRM ranges from 0.60 to 0.95 in a sys-
tematic literature review (56).
Minimal clinically important differences. Reported 
MCIDs range from 5 of 50 to 19 of 50 points (56). Neck pain 
of musculoskeletal origin seems to show a lower MCID (change 
of more than 5 points) compared with nerve- related pain (7- 13.4 
points) (56,73,74). It is important to understand that each MCID 
is disease specific and, accordingly, shows slight variations, but 
on average a change of 5 to 7 points on the NDI (10%- 14%) 
can be considered a clinically meaningful change in pain and 
disability.
Generalizability. Because of its strong psychometric prop-
erties and its cross- validation in several languages, the NDI can be 
used in a variety of different patient populations with neck pain.
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Use in clinical trials. The NDI has been used in multiple 
clinical trials (75,76).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The NDI is a reliable, valid, and responsive meas-
ure in various populations. This includes patients with both acute 
and chronic conditions as well as patients with neck pain associ-
ated with musculoskeletal dysfunction, whiplash- associated dis-
orders, and cervical radiculopathy (56,60).
Caveats and cautions. The MCID differs across study 
populations and publications, which complicates the standard-
ized interpretation of NDI results over time in clinical practice and 
research (56). The NDI does not include psychosocial and emo-
tional aspects, although these are quite common in patients with 
chronic neck pain (56). We recommend scoring the NDI out of 50 
points, as originally proposed.
Clinical usability. The NDI is one of the most common 
PROMs for neck pain and is regularly used by rheumatologists, 
spine surgeons, and physiotherapists (13,56,57). More studies 
reporting MCIDs for specific pathologies and patient populations 
are required (56).
Research usability. The good psychometric properties sup-
port using the NDI in research on cervical spine or neck diseases.
OSWESTRY DISABILITY INDEX
Description
We would like to refer to the article by Smeets et al (77) for 
a comprehensive description of the ODI. To avoid considerable 
redundancy, we provide only a brief overview and literature update 
on the ODI.
Purpose. The ODI assesses pain- related disability in 
patients with LBP associated with a wide range of causes/dis-
orders. It is especially useful in patients with severe, persistent 
disability (6). Initially published in 1980 by John O’Brian (version 
1.0), it has been modified several times (6,78,79). All versions of 
the ODI remain in use; however, not all have been subject to the 
same systematic validation as the original. The ODI version 2.0 
developed by Fairbank et al is recommended for general use and 
has been adapted by various spine societies (6,7).
Content. The ODI contains one item on pain intensity and 
nine items on activities of daily living (ADLs) (personal care, lifting, 
walking, sitting, standing, sleeping, sex life, social life, and traveling).
Number of items. Ten items.
Cost to use. No permission is required, and the question-
naire is free.
How to obtain. The ODI can be found in the original article 
(7).
Psychometric information 
The ODI has been used in multiple clinical trials (32,80,81).
Critical appraisal of overall value to the  
rheumatology community
Clinical usability. The ODI is one of the most commonly 
used clinical measures of pain- related disability in a variety of 
pathologies of the lower back. The ODI has established psy-
chometric properties, a high reliability and validity, as well as low 
respondent and administrative burden (77).
Research usability. The ODI is one of the most frequently 
used outcome questionnaires for assessing and monitoring out-
comes in both patients undergoing surgical or conservative care 
(5,82). It is frequently used as a comparator to validate other out-
come measures.
ROLAND- MORRIS DISABILITY QUESTIONNAIRE
Description
Similar to the ODI, we would like to refer to the article by 
Smeets et  al (77) for a more comprehensive description of the 
RMDQ.
Purpose. Originally designed in 1983, the RMDQ assesses 
physical disability due to LBP (83). It has been extensively used 
for acute, subacute, and chronic LBP as well as sciatica in vari-
ous clinical settings (84). Since its first publication, several mod-
ifications have been proposed to improve suitability for specific 
patients (eg, for those with sciatica). However, changes resulted 
only in minor improvements and reduced comparability (85). The 
use of the original 24- item RMDQ is therefore recommended 
(7,35).
Content. The RMDQ assesses the execution of ADLs and 
common functions (housework, sleeping, dressing, mobility, 
appetite, etc). It does not exclusively contain items to rate physical 
disability but rates general impairment and health as well.
Number of items. Twenty- four items.
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Cost to use. No permission is required, and the question-
naire is free.
How to obtain. Free download in different languages 
is available on the RMDQ website (www.rmdq.org/). A copy is 
attached in the original publication (7).
Psychometric information
The RMDQ has been used in multiple clinical trials (86–88).
Critical appraisal of overall value to the  
rheumatology community
Clinical usability. Although it is nonspecific to any spine 
pathology, the RMDQ is one of the most established and thor-
oughly evaluated measures for patients with LBP. It has psycho-
metric properties ranging from acceptable to good. However, 
scores and changes must be interpreted with caution because 
some items are poor- fitting, and the overall score does not have 
interval- level properties.
Research usability. Psychometric qualities are accept-
able for use in research. Rasch analysis and examination of score 
 distribution is recommended as part of statistical analysis (89) (see 
Tables 1 and 2).
OBJECTIVE OUTCOME MEASURES
TIMED UP- AND- GO TEST
Description
Purpose. The TUG is the most frequently applied objec-
tive task- based functional outcome measure in patients with 
lumbar degenerative disk diseases (DDDs) (8). It includes 
several activities that are difficult to perform for patients with 
painful conditions or disability resulting from lumbar DDD, 
eg, standing up, walking fast, changing direction, and sitting 
down (8,90).
Content. The patient is asked to sit and lean back on an 
armchair, with arms resting on the armrests. On command, 
the patient should get up and walk as fast as possible to a 
line marked on the floor at 3 meters away from the chair. At 
this line, the participant should turn around, walk back to 
the chair, and sit down as quickly as possible. The examiner 
records the time (in seconds) between getting up and sitting 
down again.
Cost to use. None.
How to obtain. Measurement is possible with any com-
mercial stopwatch. A smartphone application (TUG app) is availa-
ble in multiple languages and conveniently measures and scores 
the TUG test based on normal population reference values. It 
can be downloaded free of cost in the Apple App Store (https://
itunes.apple.com/de/app/tug-app/id111 90877 07?mt=8) and 
the Android Play Store (https://play.google.com/store/ apps/detai 
ls?id=ch.webge aring.tugapp).
Practical application
Method of administration. The TUG test does not 
require any special equipment except for a chair, a timer, and 
3 meters of unrestricted walking space. It is currently recom-
mended that an examiner takes the patient’s time; however, 
patient self- measurements have been found to be reliable for 
similar objective functional tests (91). Walking aids (cane, walker, 
etc) are permitted if required.
Scoring. Results are traditionally expressed as raw test times 
(in seconds). Because raw TUG test times naturally vary, it is rec-
ommended to express TUG test results in a standardized manner 
for age and sex. Standardized OFI Z scores/T scores express a 
patient’s deviation from the normal population mean and can be 
calculated conveniently using the TUG app (see How to obtain) 
(11,92–95).
Score interpretation. Expressing OFI as a standardized 
Z/T score prevents bias introduced by the high influence of the 
variables age and sex and can express disability on an interval 
scale (93,96,97). Alternatively, TUG test results can be strati-
fied according to severity into no OFI (TUG test results are less 
than the upper limit of the normal population range [ULN]), mild 
OFI (the TUG test results are between the ULN and the 33rd 
percentile of the diseased population), moderate OFI (TUG test 
results are between the 33rd and 66th percentile of the dis-
eased population), and severe OFI (TUG test results are greater 
than the 66th percentile of the diseased population) (11,95).
Administrative burden. The TUG requires very low 
administrative burden. Completion typically takes less than 1 min-
ute. The administrative burden is lower than that of most PROMs, 
and the TUG test was preferred over a set of questionnaire- based 
PROM assessments by 60% to 70% of patients (12).
Translations/adaptations. No translation is needed for 
the TUG test. It can be demonstrated to patients if language bar-
riers exist.
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Psychometric information
Floor and ceiling effects. For discriminating subjects with 
healthy spines and patients with spine disease, the ULN was set 
as the 99th percentile of the normal population’s TUG test results 
(11). In subsequent series that examined surgical candidates with 
lumbar DDD, a considerable proportion of candidates (approxi-
mately 60%) scored within the normal population range (no OFI). 
Thus, the standardized interpretation of TUG test values is likely to 
have a floor effect (11,95). There is no upper time limit for the TUG 
test, and the calculation of standardized OFI Z/T scores allows for 
the accurate determination of extreme disability without a ceiling 
effect.
Reliability. The TUG showed an excellent intrarater 
(ICC = 0.97) and interrater reliability (ICC = 0.99) with an SEM of 
0.21 to 0.23 sec (11).
Validity. Adequate convergent validity with PROMs, 
including VAS back (r = 0.25) and VAS leg pain (r = 0.29), RMDI 
(r = 0.38), and ODI (r = 0.34) as well as the Short Form 12 (SF- 
12) physical component summary (r = −0.32) and EuroQol Five 
Dimension Questionnaire (EQ- 5D) (r = −0.28) could be demon-
strated (11).
Responsiveness. Several studies demonstrated that the 
TUG test is sensitive to the postoperative change in function of 
a patient with DDD (92,94,98). The SRM is 0.51 in a sample of 
123 patients with lumbar DDD who were examined before and 6 
weeks after lumbar spine surgery (data not published).
Minimum clinically important differences. In patients 
with lumbar DDD, a change in raw TUG test time of at least 3.4 s 
is considered a clinically meaningful change in function (94).
Generalizability. The TUG test has been used in a broad 
variety of pathologies of the lumbar spine (8). Only a few studies 
so far have focused on the psychometric properties of the TUG for 
a specific disease (eg, LSS) (99).
Use in clinical trials. The TUG has been used in multiple 
clinical trials (88,90,100,101).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The TUG test is safe, fast, easy to conduct, and 
well appreciated by patients (12). It is the most thoroughly vali-
dated objective outcome measure to assess OFI in patients with 
degenerative disease of the lumbar spine (8). Its test result is (rela-
tively) independent from the confounding influence of the variables 
age and sex (11), body mass index (101), and mental health status 
(102), but it takes disability resulting from lower extremity motor 
deficits into account (103).
Caveats and cautions. The test cannot be applied to 
patients who are unable to ambulate (despite walking aid) because 
of severe pain or neurological deficits. There may be a significant 
influence of comorbidities (eg, hip or knee osteoarthritis, conges-
tive heart failure, Parkinson’s disease, etc), which renders interpre-
tation of test results in these patients difficult.
Clinical usability. Quick to conduct and interpret with-
out the need for special equipment, the TUG test can easily be 
integrated into clinical routine (administration by nursing staff, 
advanced practice providers/physician assistants, or physical 
therapists [PTs]). It should be noted that the TUG test corre-
lated moderately with a broad range of different pain, disability, 
and HRQOL measures, indicating that the TUG test can provide 
a broad impression about the patient’s general functional status. 
However, for an in- depth analysis of specific aspects of a patient’s 
condition, the assessment may need to be supplemented with 
one or several PROMs (11).
Research usability. The strong psychometric properties of 
reliability and validity paired with the low administrative burden and 
high patient acceptance demonstrate that the TUG is an accu-
rate and quick tool for the measurement of OFI in clinical spine 
research.
MOTORIZED TREADMILL TEST (MTT)
Description
Purpose. In a recent systematic review, the MTT was the 
second- most frequently applied measure to determine OFI in 
patients with lumbar DDD (8). Because of the typically long 
treadmill protocols that challenge the walking capacity of par-
ticipants, it has been primarily studied in patients with LSS and 
neurogenic claudication. The MTT has been used as an objec-
tive outcome measure in several randomized controlled trials and 
observational studies (8).
Content. The participant is instructed to walk on a cali-
brated treadmill, usually at a predefined protocol starting on a 
level surface. Different protocols in terms of speed, time, or incline 
exist without an accepted gold standard (8). Ambulation time and 
distance, walking speed, and time of onset or significant increase 
in symptoms are monitored as test results. Several studies pro-
posed a protocol that starts with 10 minutes at 2 mph, increases 
to 2.5 mph for the next 5 minutes, and then increases to 3 mph 
for an additional 5 minutes (total of 20 minutes) (104,105). Some 
protocols remain at a constant speed between 2 and 2.5 mph 
for the complete duration of the test (between 15 and 30 min-
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utes) (106–110), whereas others instruct participants to walk at 
a maximum individually selected speed for up to 15 to 30 minutes 
(111–114). Further individualized protocols exist (8).
Cost to use. The MTT requires the cost of special equip-
ment (motorized treadmill), and PTs are needed to safely admin-
ister the test.
How to obtain. MTT protocols can be adopted using pub-
lished literature. For different protocols, see the references above.
Practical application
Method of administration. The MTT requires a program-
mable motorized treadmill and trained personal to supervise pro-
tocol adherence and patient safety. In most programs, participants 
are allowed to hold one handrail for balance purposes. Using both 
handrails is restricted because it can improve walking capac-
ity and speed in LSS by allowing the patient to bending forward 
(8,112,115). In the case that a patient does not tolerate the stand-
ard speed, it is reduced by the supervisor or the test is ended. 
Some studies use safety end points (eg, 85% of predicted maximal 
heart rate [220 − age]) as an additional reason for premature test 
termination (116). Some authors state that the additional informa-
tion gained after 15 minutes of test time is negligible (117,118).
Scoring. Test results derive from 1) the time to first symp-
toms (TTFS) for general pain and/or paresthesia, 2) total ambu-
lation time (in minutes or seconds) and distance (in meters), and 
3) maximum walking speed (in m/s).
Score interpretation. All published studies so far have 
reported raw test results. No studies have expressed results in 
standardized fashion using Z- or T scores. Moreover, different 
walking protocols impede result comparisons across different 
studies (8).
Administrative burden. Test time is 15 to 30 minutes. 
In addition, the patient needs to be instructed in written or ver-
bal form, and some studies use a heart rate monitoring system. 
According to the specific walking protocol, results in different 
stages of the test can be recorded.
Translations/adaptations. No translation is needed for 
the MTT.
Psychometric information
Floor and ceiling effects. The authors are unaware of 
studies reporting on the MTT’s floor or ceiling effects. However, 
a relatively poor discriminative capacity between subjects with 
healthy spines and patients with spine disease with low disability 
burden can be assumed (similar to the TUG test). A study by Tom-
kins et al showed that the MTT likely underestimates a patient’s 
true walking capacity when compared with a different walking test 
(the self- paced walking test [SPWT]) (119).
Reliability. The MTT showed a high to excellent intrarater 
reliability, both for TTFS (ICC = 0.90- 0.98) and total ambulation 
time (ICC = 0.89- 0.96) at 1.2 mph fixed or individually selected 
walking speed (120). Another group reported slightly lower intra-
rater reliability (ICC = 0.83) with a different protocol that simulated 
a gradual increase in walking speed (121).
Validity. Convergent validity of the MTT could be demon-
strated when compared with the SPWT (r = 0.88) (119) and self- 
reported symptoms of neurogenic claudication (r = 0.88) (104) as 
well as ODI scores (r = −0.51) and self- reported walking distance 
(r = 0.62) (106).
Responsiveness. Several studies have documented the 
MTT’s good responsiveness to change in conservatively and sur-
gically treated patients with lumbar spine disease; however, no 
SRMs are reported and between- study comparisons are com-
plicated by different MTT protocols (117,122,123). Moreover, in 
a report of 32 patients undergoing surgery or conservative treat-
ment for LSS, internal responsiveness was low and was signif-
icantly worse compared with the SPWT (effect size [ES] in time 
0.17 min; ES in distance 0.09 m; ES in speed 0.11 km/h) (112).
Minimum clinically important differences. The 
authors are unaware of any studies reporting on the MTT’s MCIDs.
Generalizability. Most studies applied the MTT to patients 
with LSS because of its ability to trigger symptoms and functional 
deficits characteristic of neurogenic claudication. Within the LSS 
population, good psychometric properties have been shown. 
However, the great variety of test protocols complicates general-
izability of the results.
Use in clinical trials. The MTT has been used in multiple 
clinical trials (109,110,116).
Critical appraisal of overall value to the  
rheumatology community
Strengths. The MTT helps objectify functional impairment in 
LSS over time as well as before and after conservative or surgical 
treatment. It is validated and used in numerous studies.
Caveats and cautions. The MTT cannot be applied to 
patients who are unable to ambulate. Other comorbidities, espe-
cially hip/knee osteoarthritis and severe pulmonary and cardiac 
diseases, may represent significant confounders by limiting walking 
MALDANER AND STIENEN 192       |
capacity or by making this exercise- based test medically inadvisable. 
A certain risk of frightening or even injuring patients who are elderly 
needs to be considered and might lead to test dropouts (124).
Clinical usability. As a measure of walking capacity, the 
MTT can provide a valuable impression of a patient’s functional 
status, thereby supplementing PROM assessments, especially in 
patients with LSS. A drawback for the clinical use of the MTT is 
that it is comparably resource- intensive, requiring special equip-
ment and trained personnel.
Research usability. There is sufficient evidence of the reli-
ability and validity of the test. The MTT might increase our insight 
into the interaction of objective physiological walking capacity 
and subjective PROMs. However, the lack of a widely accepted 
standardized protocol and insufficient data on responsiveness 
and MCIDs hamper research usability and comparison between 
studies.
CONCLUSIONS
PROMs remain the current gold standard in evaluating 
patients with degenerative diseases of the spine. Ideally, they 
should become an integral part of any institution’s patient eval-
uation, both for clinical practice and research (125,126). PROMs 
help to evaluate, monitor, and compare treatment results over 
time and across populations.
The considerable variability of spinal pathologies and their 
clinical presentation led to the development of various disease- 
specific outcome measures, some of which are reviewed in this 
article (Tables 1 and 2). To remain concise and to not exceed the 
scope of this review, the authors acknowledge that there are sev-
eral other important outcome measures that are not discussed. 
These include, for example, the Scoliosis Research Society Ques-
tionnaire 22, 23, and 30, assessing patients with spinal deformi-
ties; the (modified) Japanese Orthopaedic Association Myelopathy 
Scale, assessing patients with cervical spondylotic myelopathy; 
or the Copenhagen Neck Functional Disability Scale, assess-
ing the level of functional disabilities in patients with neck pain. 
Other LBP- specific measures are the Low Back Pain Bother-
some Scale, the Low Back Pain Impact Questionnaire, and the 
National Institutes of Health Low Back Pain Minimal Dataset. In 
addition, generic outcome measures (that are not disease- specific 
instruments for spinal pathologies), such as the Patient- Reported 
Outcome Measurement Information System measures, or 
HRQOL measures, such as the SF- 12/SF- 36 or the EQ- 5D, have 
been extensively reviewed in the literature elsewhere (126,127). 
Other objective measures of function that exceed the scope of 
this paper but are systematically reviewed elsewhere include the 
SPWT, the 6- minute walking test (6WT), the five- repetition sit- to- 
stand test, the shuttle walking test, and the Short Physical Perfor-
mance Battery besides step counters (8,10,128,129).
It is clear that certain spinal diseases may require specific 
assessment tools. However, to enable comparison of pain and 
disability between individuals, disease populations, or studies, in 
the vast majority of patients, the use of a single PROM would 
suffice. Because of its good psychometric properties, popularity, 
and ubiquitous use, we recommend use of the ODI as the PROM 
of first choice in patients with degenerative diseases of the lumbar 
spine. For the same reasons, we recommend using the NDI in 
patients with degenerate cervical spine diseases presenting with 
acute or chronic neck pain.
Regarding the evaluation of pain/disability over time, a base-
line assessment, followed by 3- month and 12- month follow- up 
assessments after the initiation of treatment appears reasonable. 
Recent research indicates that most functional recovery after sur-
gery can be expected within 8 to 12 weeks (10).
The broader availability of modern technologies such as 
smartphones or wearable devices with global positioning systems 
(GPS), combined with patient demand for a more personalized 
and transparent care, drive the trend to construct detailed, accu-
rate, and intelligible medical profiles based on objective activity 
data (10,130). Tests such as the TUG test, the MTT, or the SPWT 
are already established and validated objective outcome meas-
ures used in spine care and research and can complement 
PROMs and add a further dimension to an in- depth patient evalu-
ation. Free smartphone applications that accurately measure OFI 
by determining walking capacity based on GPS coordinates (eg, 
the 6WT app) are currently validated in clinical trials and offer great 
potential for further advances in this field (129).
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ODI 10 One item on pain 
and nine items 






























Few data exist. 
Normative 
scores range 















Self- completed by 
patient
Past 24h Each item is 
given a score 













None are known 
to the author. It 
is estimated 
that an RMDQ 





















Past month 3- 5–point 
ordinal scale
SSM function: 1- 4 
points; SSM 









None are known 
to the authors.
Excellent












Past week Pain intensity 
is measure 






on a 5- point 
ordinal scale.





























































0- 4 points 
(0%- 8%): no 























TUG test – The patient is 
asked to stand 
up, walk back and 
forth 3 m, and sit 
down again as 
fast as possible, 
while time is 
measured. 
Examiner- based 
task. No special 
equipment 
required (besides 
a stopwatch, chair, 
and 3- m walking 
space). A free 
smartphone app 
(“TUG app”) is 
available.
– – Expressed as raw 






age and sex 





Patients with raw 
TUG test 
results >12 s, z 
scores >2.3, 
and T scores > 
123.0 are 
considered to 
have OFI. OFI 




into no, mild, 
moderate, and 
severe OFI.
Yes No translation 
needed; the TUG 
test has been 
used in different 
countries.
MTT – The patient is 
instructed to 
walk on a 
calibrated 
treadmill, usually 
for 15- 30 min.





– – Expressed in raw 
test times of 

















None No translation 
needed; the MTT 
has been used 
in different 
countries.
* COMI = Core Outcome Measures Index; MTT = motorized treadmill test; NDI = Neck Disability Index; ODI = Oswestry Disability Index; RMDQ = Roland- Morris Disability Questionnaire; SSM 



















































Floor and Ceiling 
Effects Reliability Validity Responsiveness MCIDs Generalizability Used in RCTs
ODI Unclear Good ICC and 
internal 
consistency
Adequate construct and 
content validity; lacks 
component of generic 
HRQOL
Good Cutoff point for 
MCID is 10 points 
or 30% score 
improvement
Excellent Yes; most widely 
used PROM for 
lumbar DDD 
RMDQ No improvement 
detected for 
scores lower 
than 4; no 




(Cronbach’s α = 
0.84- 0.93) and 
ICC are good. 
MDC and SEM 
are known but 
are influenced 




Acceptable; correlates well 
with SF- 36, ODI, Sickness 
Impact Profile, Quebec Back 
Scale, and VAS/NRS
Moderate to large 
responsiveness 
(response mean = 
0.78- 0.84 for 
improvement)
MCID = 2- 5 points 
and varies 
depending on the 
patient’s initial 












SSM Unclear Good ICC Good construct validity; high 
correlation with other 
questionnaires, including 
SF- 36 and Oxford Spinal 
Stenosis Score
SRM = 0.96- 1.43 for 
the subscales and 
SRM = 1.50 for the 
average scale
MCID = 0.5- 2 for 
SSM function and 
MCID = 0.48 for 
SSM symptoms
Specific to patients 
with LSS; less 
commonly used 
for general LBP 
population
Yes
COMI Back Some items are 
reported to 
have floor or 
ceiling effects of 
20%- 50%.
Good ICC and 
internal 
consistency
Moderate to high correlation 
with other questionnaires 
(ODI and SF- 36) 





MCID = 2- 3 points Excellent Yes
NDI Baseline scores in 











SRM = 0.60- 0.95 MCIDs range from 
5/50 to 19/50; an 
average change 
of 7 points can 
be regarded as 
clinically 
meaningful
Excellent Yes; most widely 
used PROM for 
neck pain
TUG test Likely to have a 




reliability; SEM = 
0.21- 0.23 s
Significant moderate 
correlation with various 
metrics, including VAS back/
leg, ODI, SF- 12, and EQ- 5D; 
likely to measure a different 
dimension of patient’s 
functional status compared 
with PROMs
SRM = 0.51 The MCID = 3.4 s in 
raw TUG test 
time for patients 
with lumbar DDD





MTT Unclear High to excellent 
ICC 
Good convergent validity with 
other walking tests and 
self- reported symptoms; 





no SRMs are 
available.
Unclear Relatively specific 
to LSS patients; 
less commonly 
used for general 
LBP population
Yes
* AUC = area under the curve; COMI = Core Outcome Measures Index; DDD = degenerative disk disease; EQ- 5D = EuroQol Five Dimension Questionnaire; ICC = intraclass correlation 
coefficient; LBP = low back pain; LSS = lumbar spinal stenosis; MCID = minimum clinically important difference; MDC = minimal detectable change; MTT = motorized treadmill test; NDI = 
Neck Disability Index; NRS = numeric rating scale; ODI = Oswestry Disability Index; PROM = patient- reported outcome measure; RMDQ = Roland- Morris Disability Questionnaire; SF- 12 = 
Short Form 12; SF- 36 = Short Form 36; SRM = standardized response mean; SSM = Spinal Stenosis Measure; TUG = Timed Up- and-Go; VAS = visual analog scale. 
